Subjects will be randomized into 4 study groups: 1. Placebo; 2. Anastrazole and Testosterone;
3. Dutasteride and Testosterone; and 4. Testosterone only. A 2 step euglycemic clamp, body
composition by dual X-ray absorptiometry scan, hormone and lipid assays will be performed to
monitor metabolic effects of each treatment group. We hypothesize that increasing
testosterone levels would increase lean mass, decrease fat mass and improve insulin
sensitivity. We further hypothesize that improvements in the metabolic profile would decrease
with anastrazole and improve with dutasteride, given in conjunction with T administration.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)